Aniket Nadkarni

Sodium Bicarbonate for Metabolic Acidosis in the Intensive Care Unit (SODa-BIC) trial

29 June 2026 Aniket Nadkarni Intensive Care Medicine, Uncategorized Leave a comment

Sodium Bicarbonate for Metabolic Acidosis in the Intensive Care Unit (SODa-BIC) trial The SODa-BIC Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. NEJM 2026; doi: 10.1056/NEJMoa2600526 Clinical Question In critically ill adults with metabolic acidosis (pH < 7.30) receiving vasopressors, does sodium bicarbonate decrease the risk of major adverse kidney events within 30 days compared […]

FARES II: PCC vs FFP in Cardiac Surgery

23 May 2025 Aniket Nadkarni Intensive Care Medicine, Summaries Leave a comment

Prothrombin Complex Concentrate vs Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery The FARES-II Multicenter Randomized Clinical Trial Karkouthi. JAMA 2025; doi:10.1001/jama.2025.3501 Clinical Question In adults undergoing cardiac surgery with cardiopulmonary bypass, is the use of a 4-factor prothrombin complex concentrate (PCC), compared to fresh frozen plasma (FFP), safe and efficacious in treating active or anticipated bleeding? Background Bleeding post […]

ALBICS-AKI

23 December 2024 Aniket Nadkarni Intensive Care Medicine Leave a comment

Postoperative 20% Albumin Infusion for Acute Kidney Injury in High-Risk Cardiac Surgery. Shehabi et al.. JAMA Surgery 2025; doi:10.1001/jamasurg.2025.1683 Clinical Question Amongst patients undergoing high risk cardiac surgery, does the administration of 20% Human Albumin Solution, compared to standard care, reduce the risk of post-operative acute kidney injury? The primary outcome was the occurrence of stage 1-3 AKI […]

ARiE Trial – Rifaximin for encephalopathy

1 March 2024 Aniket Nadkarni Intensive Care Medicine, Summaries Leave a comment

In critically ill adults with overt acute hepatic encephalopathy (HE) admitted to ICU, does the addition of rifaximin to broad spectrum antimicrobials affect time to resolution of HE?